Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Files NDA For I.V. Rival To Sensipar

This article was originally published in The Pink Sheet Daily

Executive Summary

The calcimimetic etelcalcetide could be administered intravenously following dialysis sessions for chronic kidney disease patients with secondary hyperparathyroidism, eliminating the high pill burden associated with Sensipar.


Related Content

Amgen Gets Parsabiv CRL, Gives No Clues As To Why
Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar


Related Companies